ICC Labs

What ICC Labs does

ICC Labs is a Uruguay-anchored medical cannabis manufacturer and the operational cannabis subsidiary of publicly listed parent Aurora Cannabis Inc. (listed as ACB on TSX and NASDAQ; also referenced under CVE:ICC). The company operates a single GMP-certified laboratory and manufacturing facility in the Parque de las Ciencias, Canelones, Uruguay, where it produces pharmaceutical-grade cannabis API (Active Pharmaceutical Ingredient) from a vertically integrated seed-to-extract-to-finished-product workflow that the company states was refined over roughly two years.

The commercial product is the Bidiol line of full-spectrum CBD oral drop solutions, available in three CBD concentrations (3%, 5%, 10%) plus orange-flavored and mint-flavored variants with integrated graduated dosing syringes. All products are registered trademarks before the MSP and are positioned as the first CBD oils produced entirely in Uruguay. Distribution is prescription-based, supplied through pharmacy networks across Uruguay and, via an exclusive-feel regional distribution agreement with Apiter (Martinez, Buenos Aires), into Argentina.

Revenue mechanics are product sales of branded CBD oils to patients via doctors' prescriptions dispensed at pharmacies. The company holds stacked Uruguayan regulatory credentials (MSP manufacturer authorization 2018 and 2019, GMP and GLP certifications 2021, and an IRCCA cannabinoid-dosing license). Headcount is reported at 51-100 employees. The investor-relevant signal is that the C$223.63 million market-cap and P/E 95.29 figures present in the source data appear to attach to the Aurora Cannabis parent listing rather than a standalone ICC Labs line of business; ICC Labs' direct revenue is not separately disclosed.

Name

ICC Labs

Legal name

ICC Labs Cannabis Inc.

Website

https://icclabs.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

ICC Labs is a Uruguayan GMP-certified medical cannabis manufacturer producing the Bidiol line of full-spectrum CBD oral drops for prescription-based distribution through pharmacies in Uruguay and Argentina, operating as the cannabis subsidiary of Aurora Cannabis.

Ownership category

akta.pro rank

Headquarters

HQ city

Montevideo

HQ country

Uruguay

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Cannabis Products: Sale of medical cannabis products including Bidiol CBD oils in various concentrations (3%, 5%, 10%) through pharmacy distribution channels in Uruguay and Argentina.
2. Product Distribution: Products distributed through pharmacies across Uruguay with plans to expand portfolio regionally.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

ICC Labs manufactures and sells pharmaceutical-grade medical cannabis extracts under the Bidiol brand, offering oral drop solutions in 3%, 5%, and 10% CBD concentrations (plus orange and mint flavored variants) produced entirely at its GMP-certified laboratory in Canelones, Uruguay. The products are distributed through pharmacies in Uruguay and Argentina via prescription from authorized doctors, targeting patients with conditions such as refractory epilepsy, chronic pain, neurological disorders, and other medical indications.

Product overview

ICC Labs offers a portfolio of medical cannabis products centered around its Bidiol brand of full-spectrum CBD cannabis extracts. The product line consists of five distinct formulations: Bidiol 3, Bidiol 5, and Bidiol 10 (standard unflavored oral drop solutions in 3%, 5%, and 10% CBD concentrations respectively), plus two flavored variants—Bidiol 3 O with orange flavor and Bidiol 10 M with mint flavor—both featuring an integrated dosing syringe for precise administration. All products are produced entirely in Uruguay at the company's GMP-certified facility in the Science Park, from seed to final product, and are authorized by Uruguay's Ministry of Public Health.

Differentiator

Problem solved

Functional benefit

Brands

• Bidiol: Medical cannabis extract product line available in 3%, 5%, and 10% CBD formulations. BIDIOL is a trademark registered by ICC Labs before the MSP. Products include BIDIOL 3, BIDIOL 5, BIDIOL 10, BIDIOL 3 O (orange flavor), and BIDIOL 10 M (mint flavor).
• BIDIOL

Products and services

• Bidiol 3 Cannabis sativa L. extract oral drop solution with 3% CBD concentration; contains 4.3g extract (equivalent to 3.0g CBD) per 100mL with THC below 0.2%; available in 10mL and 30mL dropper bottles; sold by prescription through pharmacies in Uruguay and Argentina.
• Bidiol 5 Cannabis sativa L. extract oral drop solution with 5% CBD concentration; contains 7.1g extract (equivalent to 5.0g CBD) per 100mL with THC below 0.2%; sold by prescription through pharmacies.
• Bidiol 10 Cannabis sativa L. extract oral drop solution with 10% CBD concentration; contains 14.3g extract (equivalent to 10.0g CBD) per 100mL with THC below 1%; available in 10mL and 30mL bottles; sold by prescription through pharmacies.
• Bidiol 3 O (Orange flavor) Cannabis sativa L. extract oral drop solution with orange flavor, containing 3% CBD; includes graduated 1mL dosing syringe for precise administration; available in 10mL and 30mL bottles; sold by prescription through pharmacies.
• Bidiol 10 M (Mint flavor) Cannabis sativa L. extract oral drop solution with mint flavor, containing 10% CBD; includes graduated 1mL dosing syringe for precise administration; available in 10mL and 30mL bottles; sold by prescription through pharmacies.

Quantifiable outcome

• First CBD oil 100% produced in Uruguay
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Apiterregional distributorChannel Partner/ Reseller/ DistributorApiter serves as the regional distributor for ICC Labs products in Argentina, located in Martínez, Buenos Aires. They handle product distribution and sales to pharmacies in the Argentine market.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• MediPharm Labs: Canadian GMP-certified cannabis extractor specializing in pharma-grade cannabinoid APIs and white-label finished products — directly comparable to ICC Labs' vertical extraction and API business model.
• PharmaCielo: Colombia-based cultivator and processor of standardized cannabis extracts for medical and wellness use, exporting globally — comparable in Latin American extract production, though focused upstream rather than on finished pharmaceuticals.
• Khiron Life Sciences: Colombia-based medical cannabis company focused on pharmaceutical-grade cannabinoid products, Latin American physician and pharmacy channel development, and chronic pain/neurological indications — directly comparable to ICC Labs' clinical pharmacy model in a neighboring LATAM market.
• Brains Bioceutical: Specialist manufacturer of pharmaceutical-grade cannabinoid APIs with GMP certification supplying global pharma — a close comparable in API-focused, GMP-certified cannabinoid manufacturing for B2B and clinical use.
• Clever Leaves: Colombia-based vertically integrated cannabis cultivator and manufacturer with EU GMP certification exporting APIs and finished products — a direct comparable on GMP-certified LATAM extraction and B2B API supply.

Broad incumbents

• OrganiGram Holdings: Canadian licensed producer with medical cannabis products and international ambitions, providing a relevant comparable for medical-channel cannabis companies seeking export growth.
• Canopy Growth: Large Canadian cannabis operator with established medical cannabis, pharmaceutical partnerships, and international footprint — relevant as a broad incumbent benchmark for cannabis pharmaceutical positioning and cross-border distribution.
• Aurora Cannabis: Canadian global cannabis major with medical, recreational, and international operations, and the listed parent/affiliate of ICC Labs. Comparable as the broader platform within which ICC Labs operates, though Aurora's scope is far wider than ICC Labs' Uruguay pharmaceutical business.
• Tilray Brands: Global cannabis major with medical cannabis operations across Europe, LATAM, and North America, including pharmaceutical-grade product lines. A broad incumbent with overlapping medical and international distribution capabilities.

Regional players

• Entourage Health: Canadian medical cannabis producer with focus on standardized extracts and clinical research — relevant as a North American peer in the medical cannabis extract category competing for similar prescriber and pharmacy channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ICC Labs